MicroRNA-93 inhibits inflammatory cytokine production in LPS-stimulated murine macrophages by targeting IRAK4

Yan Xu1, Huiyi Jin1, Xiaolu Yang1

  • 1Department of Ophthalmology, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, People's Republic of China; Shanghai Key Laboratory of Fundus Disease, Shanghai, People's Republic of China.

FEBS Letters
|March 20, 2014
PubMed

Insights

MicroRNA-93 (miR-93) levels decrease in endotoxin-induced uveitis (EIU), a model for ocular inflammation. This study reveals miR-93 inhibits inflammation by targeting IRAK4, suggesting its role in regulating the immune response.

Area of Science:

  • Ophthalmology
  • Immunology
  • Molecular Biology

Background:

  • Endotoxin-induced uveitis (EIU) is a key animal model for studying human anterior uveitis.
  • The precise mechanisms driving ocular inflammation in EIU are not fully understood.
  • MicroRNAs (miRNAs) are emerging as critical regulators of inflammatory processes.

Purpose of the Study:

  • To investigate the potential involvement of microRNA-mediated regulation in LPS-induced EIU.
  • To identify specific miRNAs and their targets involved in the inflammatory cascade of EIU.

Main Methods:

  • Quantification of miR-93 expression in the eyes of EIU rats and LPS-stimulated macrophages.
  • Analysis of the inhibitory effect of miR-93 on NF-κB activation and pro-inflammatory cytokines.
  • Validation of IRAK4 as a direct target of miR-93 through 3'-UTR binding assays.

Main Results:

  • miR-93 expression was significantly reduced in the eyes of EIU rats and LPS-stimulated macrophages.
  • miR-93 was found to inhibit NF-κB activation and pro-inflammatory cytokine production.
  • IRAK4 was identified as a direct target of miR-93, with miR-93 binding to the 3'-UTR of IRAK4.

Conclusions:

  • miR-93 acts as a negative regulator of the immune response in the context of EIU.
  • The miR-93/IRAK4 pathway represents a novel mechanism influencing ocular inflammation.
  • Targeting miR-93 could offer a therapeutic strategy for managing inflammatory eye conditions like uveitis.